Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine whether BIBF 1120 can be safely combined with
pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the
combination in patients with platinum-resistant ovarian cancer (phase II).